Developer docs
API playgroundTry for free, no card

Search company profiles

Beyond Celiac

Full company profile

uuid000ayok

Namestring
Beyond Celiac
Legal namestring
Beyond Celiac
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Beyond Celiac is a 501(c)(3) nonprofit patient advocacy organization founded in 2003 by Alice Bast and headquartered in Ambler, Pennsylvania. The organization serves individuals with celiac disease, their families, healthcare professionals, and biotech/pharma companies developing celiac therapeutics. Its core offerings include educational resources (Getting Started Guide, Symptoms Checklist, gluten-free recipes), a clinical trials matching tool, the Celiac Straight Talk podcast, a monthly newsletter, and the Go Beyond Celiac Insights patient survey program that generates real-world data. The organization also awards research grants and runs the Beyond Celiac Coalition, a precompetitive industry coalition launched in 2022.

The organization's business model is built on three revenue streams: individual charitable donations, grants (including a 2011 FDA grant), and venture philanthropy through its wholly-owned subsidiary Beyond Celiac Investments (BCI). BCI launched the Catalyst Program in October 2025 and has since made two disclosed pre-clinical investments — in RheumaGen (December 2025, Series A-1 for an HLA gene editing celiac gene therapy program) and Tolerance Bio (June 2026, for thymus-targeted immune tolerance restoration). In March 2026, Beyond Celiac appointed Dr. Jessica J. Lee, a 14-year FDA Division Director veteran, as Chief Regulatory Officer to expand regulatory consulting services to drug developers, marking the organization's expansion into a new B2B service line.

The organization reaches patients, families, and clinicians through a multi-channel distribution model spanning direct digital delivery via beyondceliac.org, social media (Facebook, Instagram, LinkedIn, YouTube, TikTok), community events (Town Halls, Step Beyond Celiac, Evening Beyond Celiac), an ambassador program, and a dedicated healthcare provider portal. Beyond Celiac is governed by a Board of Directors with no parent company, PE ownership, or public listing, and is rated four stars by Charity Navigator and holds a Candid/GuideStar Platinum Seal of Transparency. The organization operates exclusively within the United States and has no disclosed AI/ML technology stack, with its products framed as interactive tools and survey programs rather than software platforms.

Short descriptiontext

Beyond Celiac is a U.S. 501(c)(3) nonprofit founded in 2003 that drives celiac disease research, advocacy, and patient support through educational resources, research grants, and its venture philanthropy arm (Beyond Celiac Investments) funding pre-clinical therapeutic companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAmbler, United States
HQ citystring
Ambler
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
celiac disease research, patient advocacy services, nonprofit health organization, clinical trial matching, venture philanthropy biotech
Industry2 codes
PRIMARYHLAKAEAI
Nutrition & Malabsorption (Celiac/Short Bowel)
SECONDARYFSANAHAL
Corporate Deep Tech / R&D Commercialization CVC
NAICS code1 code
  • Professional Organizations81392
Product category
Nonprofit Health Advocacy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Donations and Charitable Contributions
TypeAffiliate Referral
Description

Beyond Celiac operates as a 501(c)(3) tax-exempt nonprofit organization. Individual donors contribute funds to support the organization's mission of accelerating celiac disease research, awareness, and patient support.

beyondceliac.org
2Venture Philanthropy / Beyond Celiac Investments (BCI)
TypeLicensing Royalties
Description

Beyond Celiac Investments (BCI), the venture philanthropy arm of Beyond Celiac, raises capital to invest in companies developing celiac disease treatments. BCI invests in pre-clinical and clinical-stage programs through its Catalyst Program, targeting companies developing noninvasive treatments targeting the immune response to gluten.

longevity.technology
3Grants
TypeAffiliate Referral
Description

Beyond Celiac has awarded millions in grants to fund celiac disease research necessary to improving patient health. The organization also received an FDA grant to study gluten in medications.

beyondceliac.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Beyond Celiac is a 501(c)(3) nonprofit patient advocacy organization that accelerates diagnosis, treatment discovery, and potential cures for celiac disease. The organization operates patient education, clinical trial matching, research grant funding, and a venture philanthropy program (Beyond Celiac Investments) that funds biotech companies developing celiac disease therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1 in 5 children with celiac disease isn't healing on the gluten-free diet, highlighting the urgent need for pharmaceutical treatments
+3 more records
Product overview1 text field

Beyond Celiac is a nonprofit patient advocacy organization that provides a comprehensive suite of educational resources, research programs, and community tools focused on accelerating treatments and finding a cure for celiac disease. The organization's core offerings include the Getting Started Guide (a comprehensive manual for newly diagnosed individuals), the Celiac Straight Talk Podcast, a Symptoms Checklist tool for identifying potential celiac disease, an extensive Gluten-Free Recipes Collection, and a Clinical Trials Matching Tool. Beyond Celiac operates through its venture philanthropy arm, Beyond Celiac Investments (BCI), which includes the Catalyst Program funding pre-clinical celiac disease treatments, and coordinates the Beyond Celiac Coalition for precompetitive research collaboration. The organization also runs patient survey programs (Go Beyond Celiac Insights), facilitates the DAISY Clinical Study, and provides Research Grants to advance celiac disease science. The organization supports the community through a Monthly Newsletter, Town Hall events, and various educational resources including the celiac disease drug development pipeline.

Product and service8 records
1Celiac Disease Symptoms Checklist
2Celiac Disease Clinical Trials Matching Tool
CategoryClinical Research Engagement Tool
3Beyond Celiac Investments (BCI)
CategoryVenture Philanthropy Program
4Beyond Celiac Catalyst Program
CategoryVenture Philanthropy Program
5Beyond Celiac Research Grants
CategoryResearch Funding Program
6Beyond Celiac Coalition
CategoryResearch Coalition Program
7DAISY Clinical Study
CategoryClinical Research Study
8Go Beyond Celiac Insights Surveys
CategoryPatient Data Research Program
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Beyond Celiac Coalition (Precompetitive Coalition)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Beyond Celiac launched a precompetitive coalition in 2022 to accelerate clinical research. The Coalition met with the FDA in 2024 to discuss strategies for making celiac disease clinical trials more patient-centric. The Coalition serves as a recognized conduit for education, exchange of information, and partnerships between patients, scientists, researchers, medical providers, pharmaceutical, diagnostic, and biotech companies, and payers.

beyondceliac.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Beyond Celiac partnered with National Minority Quality Forum to target inequalities in celiac disease diagnosis and treatment, focusing on health equity in underserved populations.

3U.S. Food and Drug Administration (FDA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2011-01-01
Description

Beyond Celiac received an FDA grant to study gluten in medications. Additionally, Dr. Jessica J. Lee, former FDA Division Director of Gastroenterology (14 years), joined as Chief Regulatory Officer to help develop the FDA's 2022 guidance on celiac disease treatment and expand regulatory consulting services for drug developers.

beyondceliac.org
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Another major U.S. nonprofit dedicated to celiac disease research, advocacy, and patient support. Directly comparable to Beyond Celiac in mission, programs (patient education, research grants, advocacy), and target audience of patients and providers.

2National Celiac Association
TypeDirect peer
Description

A patient-focused nonprofit serving the celiac and gluten-intolerant community through education, support groups, and awareness events. Directly comparable to Beyond Celiac as a community-led celiac advocacy organization.

TypeBroad incumbent
Description

The pioneering disease-focused venture philanthropy nonprofit that funded biotech development leading to CFTR modulator therapies. Comparable to Beyond Celiac as a model for BCI's venture philanthropy approach and patient-driven research funding.

TypeBroad incumbent
Description

A larger disease-focused nonprofit funding research, providing patient education, and advocating for patients with inflammatory bowel diseases. Comparable in patient advocacy, research grants, and clinical trial engagement model though focused on a different GI condition.

5National Psoriasis Foundation
TypeBroad incumbent
Description

A disease-specific nonprofit that funds research, advocates for patients, and engages with pharmaceutical developers. Comparable as a chronic autoimmune disease advocacy organization with research funding and patient community programs similar to Beyond Celiac's structure.

TypeDirect peer
Description

A disease-focused venture philanthropy organization funding melanoma research and drug development. Highly comparable to Beyond Celiac Investments (BCI) in its model of deploying philanthropic capital into pre-clinical and clinical-stage biotech programs.

TypeDirect peer
Description

A disease-specific nonprofit that combines patient advocacy, research funding, and venture philanthropy to accelerate Duchenne muscular dystrophy therapies. Comparable to Beyond Celiac in patient-led advocacy, regulatory engagement, and venture investment in therapeutic developers.

TypeEmerging player
Description

A research consortium focused on immune tolerance therapies across autoimmune diseases including celiac. Comparable to Beyond Celiac's regulatory and scientific mission in advancing immune tolerance as a therapeutic approach.

9American Autoimmune Related Diseases Association
TypeEmerging player
Description

A broader autoimmune disease nonprofit advocating across multiple conditions including celiac. Comparable to Beyond Celiac in patient advocacy and research funding, though operating at a multi-disease scale.

TypeEmerging player
Description

A nonprofit advancing rare disease therapies through patient advocacy, regulatory engagement, and venture philanthropy. Comparable to Beyond Celiac's model of combining patient community, FDA engagement, and biotech investment to accelerate treatment development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Beyond Celiac

Nonprofit Health Advocacybeyondceliac.org

Beyond Celiac is a U.S. 501(c)(3) nonprofit founded in 2003 that drives celiac disease research, advocacy, and patient support through educational resources, research grants, and its venture philanthropy arm (Beyond Celiac Investments) funding pre-clinical therapeutic companies.

What Beyond Celiac does

Beyond Celiac is a 501(c)(3) nonprofit patient advocacy organization founded in 2003 by Alice Bast and headquartered in Ambler, Pennsylvania. The organization serves individuals with celiac disease, their families, healthcare professionals, and biotech/pharma companies developing celiac therapeutics. Its core offerings include educational resources (Getting Started Guide, Symptoms Checklist, gluten-free recipes), a clinical trials matching tool, the Celiac Straight Talk podcast, a monthly newsletter, and the Go Beyond Celiac Insights patient survey program that generates real-world data. The organization also awards research grants and runs the Beyond Celiac Coalition, a precompetitive industry coalition launched in 2022.

The organization's business model is built on three revenue streams: individual charitable donations, grants (including a 2011 FDA grant), and venture philanthropy through its wholly-owned subsidiary Beyond Celiac Investments (BCI). BCI launched the Catalyst Program in October 2025 and has since made two disclosed pre-clinical investments — in RheumaGen (December 2025, Series A-1 for an HLA gene editing celiac gene therapy program) and Tolerance Bio (June 2026, for thymus-targeted immune tolerance restoration). In March 2026, Beyond Celiac appointed Dr. Jessica J. Lee, a 14-year FDA Division Director veteran, as Chief Regulatory Officer to expand regulatory consulting services to drug developers, marking the organization's expansion into a new B2B service line.

The organization reaches patients, families, and clinicians through a multi-channel distribution model spanning direct digital delivery via beyondceliac.org, social media (Facebook, Instagram, LinkedIn, YouTube, TikTok), community events (Town Halls, Step Beyond Celiac, Evening Beyond Celiac), an ambassador program, and a dedicated healthcare provider portal. Beyond Celiac is governed by a Board of Directors with no parent company, PE ownership, or public listing, and is rated four stars by Charity Navigator and holds a Candid/GuideStar Platinum Seal of Transparency. The organization operates exclusively within the United States and has no disclosed AI/ML technology stack, with its products framed as interactive tools and survey programs rather than software platforms.

Beyond Celiac firmographics

Firmographics
Name
Beyond Celiac
Legal name
Beyond Celiac
Website
https://beyondceliac.org
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
Beyond Celiac is a U.S. 501(c)(3) nonprofit founded in 2003 that drives celiac disease research, advocacy, and patient support through educational resources, research grants, and its venture philanthropy arm (Beyond Celiac Investments) funding pre-clinical therapeutic companies.
Ownership category
akta.pro rank

Beyond Celiac industry classification

Industry
Product category
Nonprofit Health Advocacy
NAICS
Professional Organizations (81392)
akta.pro industry
PRIMARYHLAKAEAI
Nutrition & Malabsorption (Celiac/Short Bowel)
SECONDARYFSANAHAL
Corporate Deep Tech / R&D Commercialization CVC

Keywords

  • Celiac disease research
  • Patient advocacy services
  • Nonprofit health organization
  • Clinical trial matching
  • Venture philanthropy biotech

Where Beyond Celiac is headquartered

Location

Headquarters

HQ city
Ambler
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Beyond Celiac business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Donations and Charitable Contributions: Beyond Celiac operates as a 501(c)(3) tax-exempt nonprofit organization. Individual donors contribute funds to support the organization's mission of accelerating celiac disease research, awareness, and patient support.
  2. Venture Philanthropy / Beyond Celiac Investments (BCI): Beyond Celiac Investments (BCI), the venture philanthropy arm of Beyond Celiac, raises capital to invest in companies developing celiac disease treatments. BCI invests in pre-clinical and clinical-stage programs through its Catalyst Program, targeting companies developing noninvasive treatments targeting the immune response to gluten.
  3. Grants: Beyond Celiac has awarded millions in grants to fund celiac disease research necessary to improving patient health. The organization also received an FDA grant to study gluten in medications.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Beyond Celiac product offering

Product offering

Core offering

Beyond Celiac is a 501(c)(3) nonprofit patient advocacy organization that accelerates diagnosis, treatment discovery, and potential cures for celiac disease. The organization operates patient education, clinical trial matching, research grant funding, and a venture philanthropy program (Beyond Celiac Investments) that funds biotech companies developing celiac disease therapeutics.

Product overview

Beyond Celiac is a nonprofit patient advocacy organization that provides a comprehensive suite of educational resources, research programs, and community tools focused on accelerating treatments and finding a cure for celiac disease. The organization's core offerings include the Getting Started Guide (a comprehensive manual for newly diagnosed individuals), the Celiac Straight Talk Podcast, a Symptoms Checklist tool for identifying potential celiac disease, an extensive Gluten-Free Recipes Collection, and a Clinical Trials Matching Tool. Beyond Celiac operates through its venture philanthropy arm, Beyond Celiac Investments (BCI), which includes the Catalyst Program funding pre-clinical celiac disease treatments, and coordinates the Beyond Celiac Coalition for precompetitive research collaboration. The organization also runs patient survey programs (Go Beyond Celiac Insights), facilitates the DAISY Clinical Study, and provides Research Grants to advance celiac disease science. The organization supports the community through a Monthly Newsletter, Town Hall events, and various educational resources including the celiac disease drug development pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Celiac Disease Symptoms Checklist
  • Celiac Disease Clinical Trials Matching Tool
  • Beyond Celiac Investments (BCI)
  • Beyond Celiac Catalyst Program
  • Beyond Celiac Research Grants
  • Beyond Celiac Coalition
  • DAISY Clinical Study
  • Go Beyond Celiac Insights Surveys

Quantifiable outcome

  • 1 in 5 children with celiac disease isn't healing on the gluten-free diet, highlighting the urgent need for pharmaceutical treatments
  • +3 more outcomes

Companies that use Beyond Celiac

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Beyond Celiac technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Beyond Celiac partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Beyond Celiac Coalition (Precompetitive Coalition)coreStrategic or Co-development Partner · 1 January 2022Beyond Celiac launched a precompetitive coalition in 2022 to accelerate clinical research. The Coalition met with the FDA in 2024 to discuss strategies for making celiac disease clinical trials more patient-centric. The Coalition serves as a recognized conduit for education, exchange of information, and partnerships between patients, scientists, researchers, medical providers, pharmaceutical, diagnostic, and biotech companies, and payers.
  • National Minority Quality ForumcoreStrategic or Co-development Partner · 1 January 2020Beyond Celiac partnered with National Minority Quality Forum to target inequalities in celiac disease diagnosis and treatment, focusing on health equity in underserved populations.
  • U.S. Food and Drug Administration (FDA)coreStrategic or Co-development Partner · 1 January 2011Beyond Celiac received an FDA grant to study gluten in medications. Additionally, Dr. Jessica J. Lee, former FDA Division Director of Gastroenterology (14 years), joined as Chief Regulatory Officer to help develop the FDA's 2022 guidance on celiac disease treatment and expand regulatory consulting services for drug developers.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Beyond Celiac competitors and assessment

Company assessment

Direct peers

  • Celiac Disease Foundation: Another major U.S. nonprofit dedicated to celiac disease research, advocacy, and patient support. Directly comparable to Beyond Celiac in mission, programs (patient education, research grants, advocacy), and target audience of patients and providers.
  • National Celiac Association: A patient-focused nonprofit serving the celiac and gluten-intolerant community through education, support groups, and awareness events. Directly comparable to Beyond Celiac as a community-led celiac advocacy organization.
  • Melanoma Research Alliance: A disease-focused venture philanthropy organization funding melanoma research and drug development. Highly comparable to Beyond Celiac Investments (BCI) in its model of deploying philanthropic capital into pre-clinical and clinical-stage biotech programs.
  • Parent Project Muscular Dystrophy: A disease-specific nonprofit that combines patient advocacy, research funding, and venture philanthropy to accelerate Duchenne muscular dystrophy therapies. Comparable to Beyond Celiac in patient-led advocacy, regulatory engagement, and venture investment in therapeutic developers.

Broad incumbents

  • Cystic Fibrosis Foundation: The pioneering disease-focused venture philanthropy nonprofit that funded biotech development leading to CFTR modulator therapies. Comparable to Beyond Celiac as a model for BCI's venture philanthropy approach and patient-driven research funding.
  • Crohn's & Colitis Foundation: A larger disease-focused nonprofit funding research, providing patient education, and advocating for patients with inflammatory bowel diseases. Comparable in patient advocacy, research grants, and clinical trial engagement model though focused on a different GI condition.
  • National Psoriasis Foundation: A disease-specific nonprofit that funds research, advocates for patients, and engages with pharmaceutical developers. Comparable as a chronic autoimmune disease advocacy organization with research funding and patient community programs similar to Beyond Celiac's structure.

Emerging players

  • Immune Tolerance Network: A research consortium focused on immune tolerance therapies across autoimmune diseases including celiac. Comparable to Beyond Celiac's regulatory and scientific mission in advancing immune tolerance as a therapeutic approach.
  • American Autoimmune Related Diseases Association: A broader autoimmune disease nonprofit advocating across multiple conditions including celiac. Comparable to Beyond Celiac in patient advocacy and research funding, though operating at a multi-disease scale.
  • EveryLife Foundation for Rare Diseases: A nonprofit advancing rare disease therapies through patient advocacy, regulatory engagement, and venture philanthropy. Comparable to Beyond Celiac's model of combining patient community, FDA engagement, and biotech investment to accelerate treatment development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Beyond Celiac social profiles

Digital presence

Beyond Celiac financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Beyond Celiac leadership team

Management profile

Number of profiles

Profiles4 records

Beyond Celiac subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Beyond Celiac funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Beyond Celiac M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beyond Celiac

What does Beyond Celiac do?

Beyond Celiac is a 501(c)(3) nonprofit patient advocacy organization that accelerates diagnosis, treatment discovery, and potential cures for celiac disease. The organization operates patient education, clinical trial matching, research grant funding, and a venture philanthropy program (Beyond Celiac Investments) that funds biotech companies developing celiac disease therapeutics.

Is Beyond Celiac a public or private company?

Beyond Celiac is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Beyond Celiac founded?

Beyond Celiac was founded in 2003. It employs 51 to 100 people.

Where is Beyond Celiac based?

Beyond Celiac is headquartered in Ambler, United States, in the North America region.

How does Beyond Celiac make money?

Three revenue lines are on record. Donations and Charitable Contributions are the primary driver. The others are venture Philanthropy / Beyond Celiac Investments (BCI) and grants.

Who are Beyond Celiac's main competitors?

Direct peers on record are Celiac Disease Foundation, National Celiac Association, Melanoma Research Alliance and Parent Project Muscular Dystrophy. Broad incumbents are Cystic Fibrosis Foundation, Crohn's & Colitis Foundation and National Psoriasis Foundation. Emerging players are Immune Tolerance Network, American Autoimmune Related Diseases Association and EveryLife Foundation for Rare Diseases.

Does Beyond Celiac have an API?

No public API is recorded for Beyond Celiac.

What industry is Beyond Celiac in?

Beyond Celiac's product category is Nonprofit Health Advocacy. Its primary akta.pro industry code is HLAKAEAI, Nutrition & Malabsorption (Celiac/Short Bowel), with a secondary code of FSANAHAL, Corporate Deep Tech / R&D Commercialization CVC. Its NAICS code is 81392.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Billy Penn at WHYYA gluten-free expo is headed to the Philly suburbs this weekendThe Wicked Gluten-Free Expo and Food Festival is taking place this Saturday at the Greater Philadelphia Expo Center in Oaks, Pennsylvania, featuring over 100 vendors offering celiac-safe food options. The event includes demonstrations, educational resources from organizations like Beyond Celiac and CHOP, and participation from various local and national brands such as Jovial Foods and A&A Soft Pretzel.EIN PresswireBeyond Celiac Appoints Turner Jenkins as Managing Director of Beyond Celiac InvestmentsBeyond Celiac announced the appointment of Turner Jenkins as Managing Director of Beyond Celiac Investments (BCI), its venture philanthropy program, effective March 9. Jenkins, who previously served as a volunteer on BCI's investment committee, brings experience from roles at Mirati Therapeutics, Curzion Pharmaceuticals, and Regulus Therapeutics, and will oversee the organization's investment portfolio to accelerate celiac disease treatments and cures. Celiac disease affects an estimated 1 in 133 Americans, with up to 83% undiagnosed, and currently has no pharmaceutical treatments or cures available.EIN PresswireBeyond Celiac Appoints Former FDA Division Director Dr. Jessica J. Lee As Chief Regulatory OfficerBeyond Celiac, a U.S.-based patient advocacy organization focused on celiac disease cure research, announced the appointment of Dr. Jessica J. Lee as Chief Regulatory Officer, effective March 2, 2026. Dr. Lee, who spent 14 years as FDA Division Director of Gastroenterology overseeing drug reviews and helped develop the FDA's 2022 guidance on celiac disease treatment, will expand the organization's regulatory consulting services for drug developers. The appointment is intended to position Beyond Celiac as a key partner for companies developing celiac therapies, from trial design through approval.PR NewswireRheumaGen Announces Funding Agreement with Beyond Celiac Investments to Accelerate Treatments Towards a Cure in Celiac DiseaseRheumaGen, Inc. announced a Series A-1 preferred stock investment from Beyond Celiac Investments (BCI) to advance its celiac disease gene therapy program through early development. This funding aims to demonstrate preclinical proof of concept for RheumaGen's HLA gene-editing platform, which targets the source of autoimmune diseases without broad immunosuppression. The investment was identified through BCI's inaugural Catalyst Program, which screens for early-stage candidates with potential for transformational efficacy in celiac disease.EIN PresswireBeyond Celiac Investments Surpasses First Year Fundraising Goal and First Investments in Celiac Disease TherapeuticsBeyond Celiac Investments (BCI) has surpassed its first-year fundraising goal and announced its first investments through its Catalyst Program, which supports pre-clinical celiac disease treatments. The program evaluated nearly 20 pre-clinical initiatives and selected three companies with distinct scientific approaches targeting the immune response to gluten, designed to bridge the funding gap that often stalls promising autoimmune research. Beyond Celiac, the parent organization driving this initiative, aims to find a cure for celiac disease by 2030 for the 3.2 million Americans affected, with final portfolio company names to be announced as negotiations are completed.PR NewswireBeyond Celiac Launches First Investment Program for Celiac Disease TherapeuticsBeyond Celiac has launched Beyond Celiac Investments (BCI), an investment program aimed at accelerating treatments and a cure for celiac disease, with an initial funding of $2 million. The program is designed to leverage venture capital strategies to identify and support promising treatments for the disease, fulfilling the fourth phase of their Science Plan to drive towards a cure by 2030. BCI aims to collaborate with venture capital firms and pharmaceutical companies to enhance drug development in the field.YahooBeyond Celiac Launches First Investment Program for Celiac Disease TherapeuticsBeyond Celiac launched Beyond Celiac Investments (BCI) to accelerate celiac disease treatments and a cure, with an initial $2 million funding and additional capital from donations. The program uses a Development Catalyst model, returning all financial returns to the organization for future investments and grants.PR NewswireTODAY's Dylan Dreyer Joins Forces with Beyond Celiac to Drive Celiac Disease Awareness and ResearchNBC News meteorologist Dylan Dreyer has partnered with the non-profit organization Beyond Celiac to raise awareness and support research for celiac disease treatments. Dreyer will serve as keynote speaker at the upcoming Summit in Connecticut and emcee for a 5K event in Massachusetts, leveraging her personal experience as a mother of a son with the condition. The collaboration aims to accelerate scientific discovery and improve the quality of life for millions affected by the autoimmune disorder.PR NewswireBeyond Celiac Celebrates 20th Anniversary Continuing Push for Treatments Leading to a Cure for Celiac Disease by 2030Beyond Celiac, a Philadelphia-based celiac disease nonprofit and the leading US funder of celiac disease research, is marking its 20th anniversary with an announcement that it has committed more than $3 million to directly fund research and registered over 8,000 patients in its online patient registry and app. The organization aims to drive treatments leading toward a cure for celiac disease by 2030, noting that the autoimmune condition affects one in 133 Americans and requires many patients to maintain a strict gluten-free diet that is not always effective. Beyond Celiac also commissioned The Harris Poll to conduct the first nationwide benchmark study on American awareness and knowledge of celiac disease.